Iterum Therapeutics plc Annual Operating Income (Loss) in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Iterum Therapeutics plc quarterly/annual Operating Income (Loss) history and growth rate from 2016 to 2023.
  • Iterum Therapeutics plc Operating Income (Loss) for the quarter ending September 30, 2024 was -$4.89M, a 70.7% increase year-over-year.
  • Iterum Therapeutics plc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$26.5M, a 39.8% increase year-over-year.
  • Iterum Therapeutics plc annual Operating Income (Loss) for 2023 was -$47.5M, a 56.2% decline from 2022.
  • Iterum Therapeutics plc annual Operating Income (Loss) for 2022 was -$30.4M, a 23.8% decline from 2021.
  • Iterum Therapeutics plc annual Operating Income (Loss) for 2021 was -$24.5M, a 23.6% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$47.5M -$17.1M -56.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 -$30.4M -$5.85M -23.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$24.5M +$7.59M +23.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-28
2020 -$32.1M +$69.9M +68.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-16
2019 -$102M -$25.5M -33.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-28
2018 -$76.6M -$47.1M -160% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-12
2017 -$29.5M -$16.1M -120% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 -$13.4M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.